Evaluation of Humoral and Cellular Responses in SARS-CoV-2 mRNA Vaccinated Immunocompromised Patients

• DOI: 10.3389/fimmu.2022.858399
• Publication Date: 2022-03-29T09:03:54Z
• Authors: Matthijs Oyaert; Marie-Angélique D...; Sophie Van Herrewege; Guy Laureys; Sofie Van Assche; Melissa Cambron; Leslie Naesens; Levi Hoste; Karlien Claes; Filomeen Haerynck; Tessa Kerre; Steven Van Laecke; Wim Van Biesen; Peggy Jacques; Bruno Verhasselt; Elizaveta Padalko
• Keywords: Humoral immunity; Primary Immunodeficiency; Cellular immunity

Immunocompromised patients are at increased risk of severe COVID-19 and impaired vaccine response. In this observational prospective study, we evaluated immunogenicity the BNT162b2 mRNA in cohorts primary or secondary immunocompromised patients.Five clinical groups [primary immunodeficiency (PID) (n=57), people living with HIV (PLWH) (n=27), a broad variety underlying rheumatologic (n=23) homogeneous (multiple sclerosis) neurologic (n=53) conditions chronic kidney disease (CKD) (n=39)] as well healthy control group (n=54) were included. Systemic humoral cellular immune responses by determination anti-SARS-CoV-2 Spike antibodies using TrimericS IgG assay (Diasorin) through quantification interferon gamma release response to SARS-CoV-2 antigen QuantiFERON (Qiagen), respectively. Responses measured pre-defined time-points after complete vaccination.All controls, PLWH CKD-patients had detectable 10 14 days (T2) 3 months (T3) administration second vaccination. contrast, only 94.5% PID, 50.0% 48.0% developed T2 89.1% 52.4% T3. At T3 no significant differences between CKD found, while proportions reactive subjects lower PID higher patients. Humoral significantly correlated control, for all antigens.Patients acquired inherited disorders may show variable vaccination against SARS-CoV-2. Whether humoral, both delayed depends on patient group, therapy individual factors. These data guide counselling regarding